This study aims to explore the therapeutic potential of Silybum marianum compounds in treating non-alcoholic fatty liver disease (NAFLD).
Utilized integrated network pharmacology to identify active compounds.
Employed molecular modeling to analyze interactions with target proteins.
Focused on silybin A and silandrin as key compounds.
Identified silybin A and silandrin as potential therapeutic scaffolds.
Demonstrated these compounds target AKT1 and MTOR pathways effectively.
Abstract
This integrative study provides a mechanistic basis for the anti-NAFLD activity of Silybum marianum, identifying silybin A and silandrin as promising scaffolds for AKT1 and MTOR-targeted therapy.